Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Celalettin Ustun, Jennifer Le-Rademacher, Hai-Lin Wang, Megan Othus, Zhuoxin Sun, Brittny Major, Mei-Jie Zhang, Elizabeth Storrick, Jacqueline M Lafky, Selina Chow, Krzysztof Mrózek, Eyal C. Attar, Clara D. Bloomfield, Larry D Cripe, Richard A. Larson, Guido Marcucci, Gail J. Roboz, Geoffrey L. Uy, Richard M. Stone, Aminah Jatoi, Thomas C. Shea, Marcos de Lima, James M. Foran, Brenda M. Sandmaier, Mark R. Litzow, Harry P. Erba, Arti Hurria, Daniel J. Weisdorf, Andrew S Artz
Institutions: University of Minnesota, Mayo Clinic, Medical College of Wisconsin, Fred Hutch Cancer Center, Harvard University, University of Chicago, University of Chicago Medicine Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Massachusetts General Hospital, Agios Pharmaceuticals (United States), The Ohio State University, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, City Of Hope National Medical Center, City of Hope, Beckman Research Institute, Cornell University, Weill Cornell Medicine, Washington University in St. Louis, Dana-Farber Cancer Institute, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida), Duke University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2909967143